Medical - Devices
Compare Stocks
5 / 10Stock Comparison
IRIX vs ATRC vs EW vs HOLX vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
IRIX vs ATRC vs EW vs HOLX vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $18M | $1.33B | $46.10B | $16.97B | $109.33B |
| Revenue (TTM) | $51M | $552M | $6.07B | $4.13B | $25.12B |
| Net Income (TTM) | $-5M | $-5M | $1.07B | $544M | $3.25B |
| Gross Margin | 38.0% | 75.5% | 78.1% | 52.8% | 63.5% |
| Operating Margin | -6.0% | -0.4% | 26.7% | 17.5% | 22.4% |
| Forward P/E | — | 428.7x | 26.6x | 17.2x | 19.1x |
| Total Debt | $5M | $88M | $705M | $2.63B | $14.86B |
| Cash & Equiv. | $2M | $167M | $2.94B | $1.96B | $4.01B |
IRIX vs ATRC vs EW vs HOLX vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| IRIDEX Corporation (IRIX) | 100 | 57.2 | -42.8% |
| AtriCure, Inc. (ATRC) | 100 | 55.0 | -45.0% |
| Edwards Lifescience… (EW) | 100 | 106.7 | +6.7% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
| Stryker Corporation (SYK) | 100 | 145.8 | +45.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IRIX vs ATRC vs EW vs HOLX vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, IRIX doesn't own a clear edge in any measured category.
ATRC ranks third and is worth considering specifically for growth exposure.
- Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
- 14.9% revenue growth vs IRIX's -6.2%
EW is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 17.6% margin vs IRIX's -10.0%
- 8.0% ROA vs IRIX's -17.9%, ROIC 15.5% vs -129.9%
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.45
- Lower volatility, beta 0.45, Low D/E 52.0%, current ratio 3.75x
- Beta 0.45, current ratio 3.75x
- Lower P/E (17.2x vs 26.6x)
SYK is the clearest fit if your priority is long-term compounding and valuation efficiency.
- 179.2% 10Y total return vs EW's 125.5%
- PEG 1.28 vs EW's 3.75
- 1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 14.9% revenue growth vs IRIX's -6.2% | |
| Value | Lower P/E (17.2x vs 26.6x) | |
| Quality / Margins | 17.6% margin vs IRIX's -10.0% | |
| Stability / Safety | Beta 0.45 vs IRIX's 1.16, lower leverage | |
| Dividends | 1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +35.3% vs SYK's -24.5% | |
| Efficiency (ROA) | 8.0% ROA vs IRIX's -17.9%, ROIC 15.5% vs -129.9% |
IRIX vs ATRC vs EW vs HOLX vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
IRIX vs ATRC vs EW vs HOLX vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EW leads in 2 of 6 categories
HOLX leads 2 • SYK leads 1 • IRIX leads 0 • ATRC leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
EW leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SYK is the larger business by revenue, generating $25.1B annually — 495.9x IRIX's $51M. EW is the more profitable business, keeping 17.6% of every revenue dollar as net income compared to IRIX's -10.0%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $51M | $552M | $6.1B | $4.1B | $25.1B |
| EBITDAEarnings before interest/tax | -$2M | $13M | $1.8B | $974M | $6.3B |
| Net IncomeAfter-tax profit | -$5M | -$5M | $1.1B | $544M | $3.2B |
| Free Cash FlowCash after capex | -$3M | $54M | $1.3B | $1000M | $4.3B |
| Gross MarginGross profit ÷ Revenue | +38.0% | +75.5% | +78.1% | +52.8% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -6.0% | -0.4% | +26.7% | +17.5% | +22.4% |
| Net MarginNet income ÷ Revenue | -10.0% | -0.8% | +17.6% | +13.2% | +12.9% |
| FCF MarginFCF ÷ Revenue | -5.6% | +9.7% | +22.0% | +24.2% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.8% | +14.3% | +13.3% | +2.5% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | +101.6% | -75.4% | -9.2% | +56.0% |
Valuation Metrics
HOLX leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 30.5x trailing earnings, HOLX trades at a 30% valuation discount to EW's 43.7x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs EW's 6.17x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $18M | $1.3B | $46.1B | $17.0B | $109.3B |
| Enterprise ValueMkt cap + debt − cash | $20M | $1.3B | $43.9B | $17.6B | $120.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.91x | -109.50x | 43.69x | 30.53x | 33.98x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 428.71x | 26.58x | 17.21x | 19.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 6.17x | — | 2.29x |
| EV / EBITDAEnterprise value multiple | — | 73.24x | 24.47x | 17.39x | 19.76x |
| Price / SalesMarket cap ÷ Revenue | 0.36x | 2.49x | 7.60x | 4.14x | 4.35x |
| Price / BookPrice ÷ Book value/share | 8.07x | 2.55x | 4.53x | 3.43x | 4.87x |
| Price / FCFMarket cap ÷ FCF | — | 27.56x | 34.53x | 18.44x | 25.53x |
Profitability & Efficiency
EW leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-109 for IRIX. EW carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRIX's 2.21x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs IRIX's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -108.7% | -1.0% | +10.4% | +11.0% | +15.0% |
| ROA (TTM)Return on assets | -17.9% | -0.7% | +8.0% | +6.1% | +6.9% |
| ROICReturn on invested capital | -129.9% | -0.6% | +15.5% | +9.4% | +11.4% |
| ROCEReturn on capital employed | -48.8% | -0.6% | +14.0% | +8.8% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 6 | 7 | 6 |
| Debt / EquityFinancial leverage | 2.21x | 0.18x | 0.07x | 0.52x | 0.66x |
| Net DebtTotal debt minus cash | $2M | -$79M | -$2.2B | $667M | $10.8B |
| Cash & Equiv.Liquid assets | $2M | $167M | $2.9B | $2.0B | $4.0B |
| Total DebtShort + long-term debt | $5M | $88M | $705M | $2.6B | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 0.47x | — | 8.00x | 6.72x |
Total Returns (Dividends Reinvested)
SYK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SYK five years ago would be worth $11,752 today (with dividends reinvested), compared to $1,377 for IRIX. Over the past 12 months, HOLX leads with a +35.3% total return vs SYK's -24.5%. The 3-year compound annual growth rate (CAGR) favors SYK at 0.8% vs IRIX's -23.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -12.0% | -33.1% | -6.3% | +1.9% | -17.8% |
| 1-Year ReturnPast 12 months | -9.6% | -15.7% | +7.1% | +35.3% | -24.5% |
| 3-Year ReturnCumulative with dividends | -54.6% | -45.0% | -10.2% | -8.5% | +2.4% |
| 5-Year ReturnCumulative with dividends | -86.2% | -64.2% | -11.5% | +16.8% | +17.5% |
| 10-Year ReturnCumulative with dividends | -90.8% | +84.4% | +125.5% | +124.3% | +179.2% |
| CAGR (3Y)Annualised 3-year return | -23.2% | -18.1% | -3.5% | -2.9% | +0.8% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than IRIX's 1.16 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ATRC's 60.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.16x | 0.95x | 0.64x | 0.45x | 0.52x |
| 52-Week HighHighest price in past year | $1.65 | $43.18 | $87.89 | $76.04 | $404.87 |
| 52-Week LowLowest price in past year | $0.87 | $26.10 | $72.30 | $53.62 | $284.97 |
| % of 52W HighCurrent price vs 52-week peak | +62.4% | +60.9% | +91.0% | +100.0% | +70.5% |
| RSI (14)Momentum oscillator 0–100 | 41.6 | 44.0 | 53.1 | 69.1 | 26.6 |
| Avg Volume (50D)Average daily shares traded | 124K | 678K | 4.7M | 10.3M | 2.1M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ATRC as "Buy", EW as "Buy", HOLX as "Hold", SYK as "Buy". Consensus price targets imply 95.3% upside for ATRC (target: $51) vs 3.9% for HOLX (target: $79). SYK is the only dividend payer here at 1.18% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $51.33 | $97.08 | $79.00 | $389.62 |
| # AnalystsCovering analysts | — | 19 | 48 | 42 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +1.2% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 34 |
| Dividend / ShareAnnual DPS | — | — | — | — | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.8% | +1.9% | +4.4% | 0.0% |
EW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). HOLX leads in 2 (Valuation Metrics, Risk & Volatility).
IRIX vs ATRC vs EW vs HOLX vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IRIX or ATRC or EW or HOLX or SYK a better buy right now?
For growth investors, AtriCure, Inc.
(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -6. 2% for IRIDEX Corporation (IRIX). Hologic, Inc. (HOLX) offers the better valuation at 30. 5x trailing P/E (17. 2x forward), making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IRIX or ATRC or EW or HOLX or SYK?
On trailing P/E, Hologic, Inc.
(HOLX) is the cheapest at 30. 5x versus Edwards Lifesciences Corporation at 43. 7x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Edwards Lifesciences Corporation's 3. 75x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — IRIX or ATRC or EW or HOLX or SYK?
Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.
5%, compared to -86. 2% for IRIDEX Corporation (IRIX). Over 10 years, the gap is even starker: SYK returned +179. 2% versus IRIX's -90. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IRIX or ATRC or EW or HOLX or SYK?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 45β versus IRIDEX Corporation's 1. 16β — meaning IRIX is approximately 155% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 2% for IRIDEX Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — IRIX or ATRC or EW or HOLX or SYK?
By revenue growth (latest reported year), AtriCure, Inc.
(ATRC) is pulling ahead at 14. 9% versus -6. 2% for IRIDEX Corporation (IRIX). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IRIX or ATRC or EW or HOLX or SYK?
Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.
7% net margin versus -18. 3% for IRIDEX Corporation — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus -17. 1% for IRIX. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IRIX or ATRC or EW or HOLX or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Edwards Lifesciences Corporation's 3. 75x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Hologic, Inc. (HOLX) trades at 17. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 411. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.
08Which pays a better dividend — IRIX or ATRC or EW or HOLX or SYK?
In this comparison, SYK (1.
2% yield) pays a dividend. IRIX, ATRC, EW, HOLX do not pay a meaningful dividend and should not be held primarily for income.
09Is IRIX or ATRC or EW or HOLX or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, IRIX: -90. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IRIX and ATRC and EW and HOLX and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
SYK pays a dividend while IRIX, ATRC, EW, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.